9:00 AM - 5:00 PM

Our Hours Mon. - Fri.

310.774.1437

Call Us For Free Consultation

Facebook

Twitter

Davis Polk, Wachtell Build Gilead’s $21B Immunomedics Buy

Tiomkin Law Offices of Elliott Tiomkin > Legal News  > Davis Polk, Wachtell Build Gilead’s $21B Immunomedics Buy

Davis Polk, Wachtell Build Gilead’s $21B Immunomedics Buy

Law360 (September 13, 2020, 5:40 PM EDT) — Gilead Sciences, led by Davis Polk, will pay $21 billion for Wachtell Lipton-advised drug development firm Immunomedics, the companies said Sunday, in a deal that represents at least the fourth major acquisition by Gilead since the start of the pandemic.

The transaction provides Foster City, California-based Gilead Sciences Inc. with a Morris Plains, New Jersey-headquartered drugmaker that makes treatments for multiple types of cancers, including breast and bladder, according to a statement. Immunomedics has multiple drugs that are in clinical trials and either have received or are awaiting approvals from regulators, in both the U.S. and Europe.

“This acquisition represents significant…

Call Now ButtonCall For Free Consultation